Undisclosed In Vivo CAR-M therapeutic
/ Liberate Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 05, 2026
Liberate Bio, Inc…announces that it has secured exclusive and non-exclusive licenses to key patents covering chimeric antigen receptor (CAR) designs optimized for myeloid cells, including monocytes and macrophages.
(Businesswire)
- "With both optimized CAR-sequence IP and cell-selective delivery technology, Liberate Bio now integrates the critical components needed to advance in vivo CAR-M therapies toward clinical evaluation....Liberate Bio plans to advance its first in vivo CAR-M candidate toward IND-enabling studies, with the goal of supporting the first clinical evaluation in the second half of 2026 through an investigator-initiated trial."
Licensing / partnership • New trial • Oncology
1 to 1
Of
1
Go to page
1